Abstract:Abstract It has been suggested that tumor re-growth, as well as chemotherapy resistance and metastasis, are dependent on a small sub-population of cancer cells within the tumor that are thought to represent cancer stem cells (CSCs), i.e. self-renewing cells with pluripotent potential and tumor forming ability. We and others have shown that putative ovarian CSCs are in a transitional phase between epithelial and mesenchymal cell stages and that considerable plasticity exists between non-CSCs and CSCs (1). These transitions are based on epigenomic changes involving either epithelial-to-mesenchymal transition (EMT) or the reverse process mesenchymal-to-epithelial transition (MET). Here we report that primary ovarian cancer cells treated with the chemotherapeutic drug cisplatin undergo partial MET-like changes in culture and in xenograft tumors. These changes involve the upregulation of epithelial markers (e.g. E-cadherin) and the downregulation of mesenchymal markers (e.g. vimentin). Cisplatin-triggered MET was also observed using a luciferase reporter system that is responsive to MAP-Kinase activation. Concurrently with the induction of MET, cisplatin treatment of primary ovarian cancer cells enriched for CSCs that were positive for the stem cell markers Nanog, Oct4, and Sox2, indicating that the formation of CSC involves MET-like events. We therefore hypothesized that compounds that block MET counteract the trans-differentiation into chemoresistant CSCs and increase the efficacy of chemotherapy. Notably, MET initiates and is required for the nuclear reprogramming of fibroblasts into induced pluripotent stem (iPS) cells indicating similarities in the formation of iPS cells and CSCs. We therefore screened 30 compounds from a library of small molecules, which has previously been generated to study EMT/MET signaling in iPS cells. We identified compounds (e.g. compound GHDM1516) that blocked MET and the formation of CSCs in primary ovarian cancer cultures. Pre-treatment of cancer cells with GHDM1516 significantly increased cisplatin induced apoptosis/necrosis in CSCs as assessed by flow cytometry for Annexin V/7-AAD. In contrast, compounds that promoted EMT (e.g. compound SD83) acted synergistically with cisplatin and increased the number of CSCs and cisplatin-resistant cancer cells. Our data indicate that it might be possible to sensitize late stage tumors to chemotherapy by interfering with pathways that are involved in the formation and maintenance of CSCs. Our findings also suggest that similarities in iPS and CSC formation can be exploited to find new cancer treatments that are targeted towards CSCs. 1. Strauss, R., Z. Y. Li, Y. Liu, I. Beyer, J. Persson, P. Sova, T. Moller, S. Pesonen, A. Hemminki, P. Hamerlik, C. Drescher, N. Urban, J. Bartek, and A. Lieber. 2011. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 6:e16186. Citation Format: Kamola Saydaminova, Robert Strauss, Charles Drescher , Andre Lieber. Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation and maintenance of cancer stem cells [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-THER-1439.

Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer

Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Abstract A033: The transcriptional landscape of cisplatin resistance and its relationship with epithelial mesenchymal transition in ovarian cancer

Abstract B003: A multi-omic analysis to identify epigenetic drivers of platinum-resistance in high-grade serous ovarian carcinoma models

Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer

Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells

A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance

CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer

Abstract A035: Genome-wide CRISPRi screening reveals determinants of platinum sensitivity and resistance in high-grade serous ovarian cancer

Sensitizing Ovarian Cancer Cells to Chemotherapy by Interfering with Pathways That Are Involved in the Formation and Maintenance of Cancer Stem Cells

Abstract A112: Mechanisms underlying platinum-induced ovarian cancer stem cell plasticity

Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells.

Targeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer

Targeting the Cdc2-like kinase 2 for overcoming platinum resistance in ovarian cancer

Impairment of Drug Response Cascades, by DNA Methylation, in Platinum-Resistant Ovarian Cancer.

CD10−/ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy

Platinum resistance induces diverse evolutionary trajectories in high grade serous ovarian cancer

Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis

Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells